JGJulien Grogg

Julien Grogg

*This is an algorithmically generated author record based on publicly available information.

Julien Grogg has a total of 42 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • A novel Encapsulated-Cell technology for the delivery of therapeutic proteins : from bench to bedside

    by Julien Grogg

    Une nouvelle technologie de cellules encapsulées pour l'administration de protéines thérapeutiques : du laboratoire au chevet du patient: La thérapie cellulaire encapsulée présente un grand potentiel pour délivrer des niveaux soutenus de protéines thérapeutiques aux patients et améliorer la gestion des maladies chroniques. Cependant, le saut translationnel vers le succès clinique est entravé par le manque de lignée cellulaire allogénique adaptée aux applications thérapeutiques humaines, ainsi que le manque d'un dispositif d'encapsulation polyvalent, biocompatible, et facile à administrer, à récupérer ou à remplacer. Dans ce travail, nous présentons le développement d'un dispositif de macroencapsulation biocompatible, cargo-agnostique et doté de caractéristiques optimisées pour l'administration de protéines. Ce dispositif est compatible avec les cellules adhérentes et en suspension, et peut être administré et récupéré sans procédures chirurgicales lourdes. Nous avons montré que différentes lignées cellulaires produisant différentes protéines thérapeutiques peuvent être combinées dans le dispositif. Parallèlement, nous avons généré une lignée cellulaire de myoblastes humains immortalisés (IHM) stable qui peut être modifiée génétiquement pour sécréter diverses protéines fonctionnelles. Nous avons encapsulé ces deux composants et évalué leur combinaison à la fois in vitro et in vivo pour la délivrance de protéines à long terme. Nous avons démontré la capacité des cellules IHM sécrétant une cytokine, encapsulées dans notre dispositif et implantées dans la peau humaine, à mobiliser et à activer les cellules présentatrices d'antigènes, ce qui pourrait potentiellement servir de stratégie adjuvante efficace dans les thérapies d'immunisation contre le cancer. Enfin, nous avons étudié l'efficacité de l'administration soutenue de faibles doses d'anti-CTLA-4 humain délivré par nos cellules IHM encapsulées dans notre dispositif, dans la région péritumorale de souris hCTLA4 knock-in greffées par voie sous-cutanée avec des cellules d'adénocarcinome du côlon MC38. Dans l'ensemble, nos résultats montrent que notre technologie peut contribuer aux thérapies cellulaires contre le cancer et, potentiellement, contre les troubles métaboliques et les maladies dues à une déficience en protéines.

  • Open Access

    Table S1 from A First-in-Human Phase I Clinical Study with MVX-ONCO-1, a Personalized Active Immunotherapy, in Patients with Advanced Solid Tumors

    by Rémi Vernet, Eugenio Fernandez, Denis Migliorini, Virginie Ancrenaz, Emily Charrier, Marie-Claude Belkouch, Olivier Von Rohr, Muriel Urwyler, Claudio De Vito, Jessica Renaux, et al.

    Representativeness of Study Participants

  • Open Access

    Figure 2 from A First-in-Human Phase I Clinical Study with MVX-ONCO-1, a Personalized Active Immunotherapy, in Patients with Advanced Solid Tumors

    by Rémi Vernet, Eugenio Fernandez, Denis Migliorini, Virginie Ancrenaz, Emily Charrier, Marie-Claude Belkouch, Olivier Von Rohr, Muriel Urwyler, Claudio De Vito, Jessica Renaux, et al.

    Trial profile. A screened population included all patients who were screened. A safety population comprised 34 treated patients who received at least one dose of the study treatment. The ITT set comprised all patients who had received at least one dose (defined as at least 1-day application without removal of the macrocapsules) of the study treatment and for whom a week 6 post-baseline efficacy measurement was available.

  • Open Access

    Figure 1 from A First-in-Human Phase I Clinical Study with MVX-ONCO-1, a Personalized Active Immunotherapy, in Patients with Advanced Solid Tumors

    by Rémi Vernet, Eugenio Fernandez, Denis Migliorini, Virginie Ancrenaz, Emily Charrier, Marie-Claude Belkouch, Olivier Von Rohr, Muriel Urwyler, Claudio De Vito, Jessica Renaux, et al.

    Treatment and immune monitoring schema.

  • Open Access

    Figure 3 from A First-in-Human Phase I Clinical Study with MVX-ONCO-1, a Personalized Active Immunotherapy, in Patients with Advanced Solid Tumors

    by Rémi Vernet, Eugenio Fernandez, Denis Migliorini, Virginie Ancrenaz, Emily Charrier, Marie-Claude Belkouch, Olivier Von Rohr, Muriel Urwyler, Claudio De Vito, Jessica Renaux, et al.

    Antitumor activity of MVX-ONCO-1. A, Waterfall plot of the maximum percentage of tumor size change in each patient. B, Percentage changes from baseline of tumor size (sum of longitudinal change of recorded lesions) over time in each patient.

  • Open Access

    Table S1 from A First-in-Human Phase I Clinical Study with MVX-ONCO-1, a Personalized Active Immunotherapy, in Patients with Advanced Solid Tumors

    by Rémi Vernet, Eugenio Fernandez, Denis Migliorini, Virginie Ancrenaz, Emily Charrier, Marie-Claude Belkouch, Olivier Von Rohr, Muriel Urwyler, Claudio De Vito, Jessica Renaux, et al.

    Representativeness of Study Participants

  • Open Access

    Data from A First-in-Human Phase I Clinical Study with MVX-ONCO-1, a Personalized Active Immunotherapy, in Patients with Advanced Solid Tumors

    by Rémi Vernet, Eugenio Fernandez, Denis Migliorini, Virginie Ancrenaz, Emily Charrier, Marie-Claude Belkouch, Olivier Von Rohr, Muriel Urwyler, Claudio De Vito, Jessica Renaux, et al.

    Over two decades, most cancer vaccines failed clinical development. Key factors may be the lack of efficient priming with tumor-specific antigens and strong immunostimulatory signals. MVX-ONCO-1, a personalized cell-based cancer immunotherapy, addresses these critical steps utilizing clinical-grade material to replicate a successful combination seen in experimental models: inactivated patient’s own tumor cells, providing the widest cancer-specific antigen repertoire and a standardized, sustained, local delivery over days of a potent adjuvant achieved by encapsulated cell technology. We conducted an open-label, single-arm, first-in-human phase I study with MVX-ONCO-1 in patients with advanced refractory solid cancer. MVX-ONCO-1 comprises irradiated autologous tumor cells coimplanted with two macrocapsules containing genetically engineered cells producing granulocyte–macrophage colony-stimulating factor. Patients received six immunizations over 9 weeks without maintenance therapy. Primary objectives were safety, tolerability, and feasibility, whereas secondary objectives focused on efficacy and immune monitoring. Data from 34 patients demonstrated safety and feasibility with minor issues. Adverse events included one serious adverse event possibly related to investigational medicinal product and two moderate-related adverse events. More than 50% of the patients with advanced and mainly nonimmunogenic tumors showed clinical benefits, including partial responses, stable diseases, and prolonged survival. In recurrent/metastatic head and neck squamous cell carcinoma, one patient achieved a partial response, whereas another survived for more than 7 years without anticancer therapy for over 5 years. MVX-ONCO-1 is safe, well tolerated, and beneficial across several tumor types. Ongoing phase IIa trials target patients with advanced recurrent/metastatic head and neck squamous cell carcinoma after initial systemic therapy.Significance:This first-in-human phase I study introduces a groundbreaking approach to personalized cancer immunotherapy, addressing limitations of traditional strategies. By combining autologous irradiated tumor cells as a source of patient-specific antigens and utilizing encapsulated cell technology for localized, sustained delivery of granulocyte–macrophage colony-stimulating factor as an adjuvant, the study shows a very good safety and feasibility profile. This innovative approach holds the promise of addressing tumor heterogeneity by taking advantage of each patient's antigenic repertoire.

  • Open Access

    Table S1 from A First-in-Human Phase I Clinical Study with MVX-ONCO-1, a Personalized Active Immunotherapy, in Patients with Advanced Solid Tumors

    by Rémi Vernet, Eugenio Fernandez, Denis Migliorini, Virginie Ancrenaz, Emily Charrier, Marie-Claude Belkouch, Olivier Von Rohr, Muriel Urwyler, Claudio De Vito, Jessica Renaux, et al.

    Representativeness of Study Participants

  • Open Access

    Data from A First-in-Human Phase I Clinical Study with MVX-ONCO-1, a Personalized Active Immunotherapy, in Patients with Advanced Solid Tumors

    by Rémi Vernet, Eugenio Fernandez, Denis Migliorini, Virginie Ancrenaz, Emily Charrier, Marie-Claude Belkouch, Olivier Von Rohr, Muriel Urwyler, Claudio De Vito, Jessica Renaux, et al.

    Over two decades, most cancer vaccines failed clinical development. Key factors may be the lack of efficient priming with tumor-specific antigens and strong immunostimulatory signals. MVX-ONCO-1, a personalized cell-based cancer immunotherapy, addresses these critical steps utilizing clinical-grade material to replicate a successful combination seen in experimental models: inactivated patient’s own tumor cells, providing the widest cancer-specific antigen repertoire and a standardized, sustained, local delivery over days of a potent adjuvant achieved by encapsulated cell technology. We conducted an open-label, single-arm, first-in-human phase I study with MVX-ONCO-1 in patients with advanced refractory solid cancer. MVX-ONCO-1 comprises irradiated autologous tumor cells coimplanted with two macrocapsules containing genetically engineered cells producing granulocyte–macrophage colony-stimulating factor. Patients received six immunizations over 9 weeks without maintenance therapy. Primary objectives were safety, tolerability, and feasibility, whereas secondary objectives focused on efficacy and immune monitoring. Data from 34 patients demonstrated safety and feasibility with minor issues. Adverse events included one serious adverse event possibly related to investigational medicinal product and two moderate-related adverse events. More than 50% of the patients with advanced and mainly nonimmunogenic tumors showed clinical benefits, including partial responses, stable diseases, and prolonged survival. In recurrent/metastatic head and neck squamous cell carcinoma, one patient achieved a partial response, whereas another survived for more than 7 years without anticancer therapy for over 5 years. MVX-ONCO-1 is safe, well tolerated, and beneficial across several tumor types. Ongoing phase IIa trials target patients with advanced recurrent/metastatic head and neck squamous cell carcinoma after initial systemic therapy.Significance:This first-in-human phase I study introduces a groundbreaking approach to personalized cancer immunotherapy, addressing limitations of traditional strategies. By combining autologous irradiated tumor cells as a source of patient-specific antigens and utilizing encapsulated cell technology for localized, sustained delivery of granulocyte–macrophage colony-stimulating factor as an adjuvant, the study shows a very good safety and feasibility profile. This innovative approach holds the promise of addressing tumor heterogeneity by taking advantage of each patient's antigenic repertoire.

  • Open Access

    Table 1 from A First-in-Human Phase I Clinical Study with MVX-ONCO-1, a Personalized Active Immunotherapy, in Patients with Advanced Solid Tumors

    by Rémi Vernet, Eugenio Fernandez, Denis Migliorini, Virginie Ancrenaz, Emily Charrier, Marie-Claude Belkouch, Olivier Von Rohr, Muriel Urwyler, Claudio De Vito, Jessica Renaux, et al.

    Patient demographics and baseline characteristics